相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
H. Avet-Loiseau et al.
LEUKEMIA (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
Kai Neben et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
Shaji Kumar et al.
BLOOD (2012)
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma
Shaji K. Kumar et al.
CANCER (2012)
Prognostic significance of HOXB4 in de novo acute myeloid leukemia
Shigeaki Umeda et al.
HEMATOLOGY (2012)
The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
Kenneth C. Anderson
JOURNAL OF CLINICAL ONCOLOGY (2012)
A gene expression signature for high-risk multiple myeloma
R. Kuiper et al.
LEUKEMIA (2012)
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Dirk Hose et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma
P. Kapoor et al.
LEUKEMIA (2011)
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Pierre Wijermans et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
Shaji K. Kumar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
High-risk myeloma: a gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
Fenghuang Zhan et al.
BLOOD (2008)
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome
Olivier Decaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma
Hermann Brenner et al.
BLOOD (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
Herve Avet-Loiseau et al.
BLOOD (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party
BM Augustson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
D Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
B Sirohi et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
